{"entity":{"edinet_code":"E00928","sec_code":"4512","name_ja":"わかもと製薬株式会社","name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","industry":"医薬品","industry_en":"Pharmaceutical"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YDBU","filer_name":"わかもと製薬株式会社","filer_name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","period_end":"2026-03-31","filed_date":"2026-06-18","sha256":"d2c968315a2e68bb3448d88b080f75e5833259cb8f8faaeead05a7b1537164ae","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"parent_only","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The reporting company itself (提出会社) — the holding company, excluding the group holders it names separately.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"キッセイ薬品工業㈱","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":200000,"book_value_yen":930000000,"prior_shares":200000,"prior_book_value_yen":769000000,"purpose_ja":"グローバル事業における顧客でもあり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.4824847773037231,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":7.744462064252221,"pct_of_holder_assets":5.636497887495138,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ロート製薬㈱","held_name_en":"ROHTO PHARMACEUTICAL CO.,LTD.","held_sec_code":"4527","match_status":"matched","shares":217500,"book_value_yen":523631000,"prior_shares":217500,"prior_book_value_yen":486438000,"purpose_ja":"包括的業務提携を締結しており、取引関係の維持・強化のため保有しております。","reciprocal":"有","pct_outstanding":0.09625413854072795,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":4.360473564695113,"pct_of_holder_assets":3.173596801426846,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"養命酒製造㈱","held_name_en":"YOMEISHU SEIZO CO., LTD.","held_sec_code":"2540","match_status":"matched","shares":62500,"book_value_yen":252500000,"prior_shares":62500,"prior_book_value_yen":183812000,"purpose_ja":"ヘルスケア業界の情報収集等による企業価値向上のため保有しております。","reciprocal":"有","pct_outstanding":0.4488813875821453,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.1026630873372967,"pct_of_holder_assets":1.5303394802070134,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"大木ヘルスケアホールディングス㈱","held_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","held_sec_code":"3417","match_status":"matched","shares":95022,"book_value_yen":126474000,"prior_shares":92632,"prior_book_value_yen":74198000,"purpose_ja":"同社傘下の企業がヘルスケア事業における顧客であり、取引関係の維持・強化のため保有しています。また、取引先持株会において継続的に取得しているため株式数が増加しています。","reciprocal":"有","pct_outstanding":0.6967443906731192,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.0531968764669197,"pct_of_holder_assets":0.7665273481968389,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱みずほフィナンシャルグループ","held_name_en":"Mizuho Financial Group, Inc.","held_sec_code":"8411","match_status":"matched","shares":19342,"book_value_yen":117734000,"prior_shares":19342,"prior_book_value_yen":78354000,"purpose_ja":"主要な金融機関として取引関係を緊密にし、長期的な財務の安定性維持のため保有しています。","reciprocal":"有","pct_outstanding":0.0007921224502674037,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9804155878200763,"pct_of_holder_assets":0.7135563895552179,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱スズケン","held_name_en":"SUZUKEN CO.,LTD.","held_sec_code":"9987","match_status":"matched","shares":18579,"book_value_yen":110266000,"prior_shares":18579,"prior_book_value_yen":91780000,"purpose_ja":"医薬事業における顧客であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.02746832604392945,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9182267247062746,"pct_of_holder_assets":0.6682947054435903,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱三菱ＵＦＪフィナンシャル・グループ","held_name_en":"Mitsubishi UFJ Financial Group, Inc.","held_sec_code":"8306","match_status":"matched","shares":32580,"book_value_yen":84708000,"prior_shares":32580,"prior_book_value_yen":65518000,"purpose_ja":"主要な金融機関として取引関係を緊密にし、長期的な財務の安定性維持のため保有しています。","reciprocal":"有","pct_outstanding":0.00028841178650907605,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7053955833749217,"pct_of_holder_assets":0.5133940462945572,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":31804,"book_value_yen":29291000,"prior_shares":31804,"prior_book_value_yen":28210000,"purpose_ja":"同社傘下の企業が医薬事業における顧客であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.15471731156536714,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2439172455096901,"pct_of_holder_assets":0.17752544045443022,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"朝日印刷㈱","held_name_en":"ASAHI PRINTING CO.,LTD.","held_sec_code":"3951","match_status":"matched","shares":32000,"book_value_yen":27968000,"prior_shares":32000,"prior_book_value_yen":28768000,"purpose_ja":"医薬事業、ヘルスケア事業、グローバル事業における仕入先であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.15470798891265858,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.23290012366989904,"pct_of_holder_assets":0.16950706765318713,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"共同印刷㈱","held_name_en":"Kyodo Printing Co., Ltd.","held_sec_code":"7914","match_status":"matched","shares":8100,"book_value_yen":12862000,"prior_shares":8100,"prior_book_value_yen":8343000,"purpose_ja":"ヘルスケア事業における仕入先であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.028347151111313314,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10710674308646459,"pct_of_holder_assets":0.07795337185909944,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ニプロ㈱","held_name_en":"NIPRO CORPORATION","held_sec_code":"8086","match_status":"matched","shares":8000,"book_value_yen":12416000,"prior_shares":8000,"prior_book_value_yen":10868000,"purpose_ja":"同社傘下の企業が医薬事業、グローバル事業における仕入先及び顧客であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.004887135306003915,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10339273224704901,"pct_of_holder_assets":0.07525027717326843,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱バイタルケーエスケー・ホールディングス","held_name_en":"VITAL KSK HOLDINGS,INC.","held_sec_code":"3151","match_status":"matched","shares":6615,"book_value_yen":9690000,"prior_shares":6615,"prior_book_value_yen":8321000,"purpose_ja":"同社傘下の企業が医薬事業における顧客であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":0.013645624996029051,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08069229828236991,"pct_of_holder_assets":0.058728671537449345,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ツルハホールディングス","held_name_en":"TSURUHA HOLDINGS INC.","held_sec_code":"3391","match_status":"matched","shares":1150,"book_value_yen":2852000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"同社傘下の企業がヘルスケア事業における顧客であり、取引関係の維持・強化のため保有しています。ウエルシアホールディングス㈱との株式交換に伴い増加しています。","reciprocal":"無","pct_outstanding":0.0002531464507910045,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.023749683663706812,"pct_of_holder_assets":0.017285260188318424,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":["share exchange"],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アステナ・ホールディングス㈱","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":5917,"book_value_yen":2792000,"prior_shares":5917,"prior_book_value_yen":2680000,"purpose_ja":"同社傘下の企業がグローバル事業における仕入先及び顧客であり、取引関係の維持・強化のため保有しています。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.023250040949884088,"pct_of_holder_assets":0.016921615163318738,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ウエルシアホールディングス㈱","held_name_en":"WELCIA HOLDINGS CO., LTD.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":1006,"prior_book_value_yen":2177000,"purpose_ja":"同社傘下の企業がヘルスケア事業における顧客であり、取引関係の維持・強化のため保有していましたが、㈱ツルハホールディングスによる完全子会社化に伴う株式交換により減少しています。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":["share exchange"],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"ロート製薬株式会社","holder_name_en":"ROHTO PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4527","doc_id":"S100YE5N","period_end":"2026-03-31","holder_table":"reporting","shares":3971900,"book_value_yen":1394000000,"prior_shares":3971900,"prior_book_value_yen":1259000000,"purpose_ja":"同社とは、医療用眼科医薬品の開発推進を目的として、共同開発・販売及び乳酸菌を活用した製品開発等に関する包括的業務提携を締結しております。これらの関係を通じたシナジー創出により、中長期的な企業価値の向上を図ることを目的として、同社株式を保有しております。","reciprocal":"有","pct_outstanding":11.444443564031214,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.435388257634911,"pct_of_holder_assets":0.2869664924419119,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キッセイ薬品工業株式会社","holder_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","holder_sec_code":"4547","doc_id":"S100YFN3","period_end":"2026-03-31","holder_table":"reporting","shares":3778000,"book_value_yen":1326000000,"prior_shares":3778000,"prior_book_value_yen":1197000000,"purpose_ja":"同社は医薬品事業における取引先の一つであるため、取引関係維持・強化のために株式を保有しています。具体的には、眼科用薬剤の仕入先です。2026年４月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しています。","reciprocal":"有","pct_outstanding":10.88574933530802,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5726971183746804,"pct_of_holder_assets":0.4820310739187018,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":231536000000,"holder_total_assets_yen":275086000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"共同印刷株式会社","holder_name_en":"Kyodo Printing Co., Ltd.","holder_sec_code":"7914","doc_id":"S100YF86","period_end":"2026-03-31","holder_table":"reporting","shares":492100,"book_value_yen":172000000,"prior_shares":492100,"prior_book_value_yen":155000000,"purpose_ja":"生活・産業資材事業において、主に紙器製品の製造及び販売を行っており、重要な取引先であることから、事業上の関係強化を図るため継続して保有しております。","reciprocal":"有","pct_outstanding":1.4179135118859387,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.26355710148480715,"pct_of_holder_assets":0.1389326419011155,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":65261000000,"holder_total_assets_yen":123801000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"朝日印刷株式会社","holder_name_en":"ASAHI PRINTING CO.,LTD.","holder_sec_code":"3951","doc_id":"S100YEXW","period_end":"2026-03-31","holder_table":"reporting","shares":410327,"book_value_yen":144000000,"prior_shares":401223,"prior_book_value_yen":127000000,"purpose_ja":"医薬品パッケージ等の取引先であり、安定的・長期的な取引関係の維持・強化を目的に保有しております。定量的な保有効果については秘密保持の観点から記載しておりませんが、保有意義や取引状況、経済合理性を取締役会において検証し、保有の合理性があると判断しております。また、持株会を通じた取得に伴い株式数が増加しております。","reciprocal":"有","pct_outstanding":1.1822966827710255,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.39199673336055535,"pct_of_holder_assets":0.20816769063968196,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":36735000000,"holder_total_assets_yen":69175000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社スズケン","holder_name_en":"SUZUKEN CO.,LTD.","holder_sec_code":"9987","doc_id":"S100YFRU","period_end":"2026-03-31","holder_table":"reporting","shares":385000,"book_value_yen":135000000,"prior_shares":385000,"prior_book_value_yen":122000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"有","pct_outstanding":1.1093206707500232,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.032450986990759885,"pct_of_holder_assets":0.011680565097087127,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大正製薬ホールディングス株式会社","holder_name_en":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","holder_sec_code":"4581","doc_id":"S100R80T","period_end":"2023-03-31","holder_table":"reporting","shares":503000,"book_value_yen":124000000,"prior_shares":1000000,"prior_book_value_yen":289000000,"purpose_ja":"当社セルフメディケーション事業における協業のために保有しています。","reciprocal":"無","pct_outstanding":1.4492743183836703,"pct_unavailable":null,"pct_basis_period_end":"2023-03-31","pct_share_classes":1,"pct_of_holder_equity":0.015321069064661089,"pct_of_holder_assets":0.013170612539697714,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":809343000000,"holder_total_assets_yen":941490000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"養命酒製造株式会社","holder_name_en":"YOMEISHU SEIZO CO., LTD.","holder_sec_code":"2540","doc_id":"S100YK3W","period_end":"2026-03-31","holder_table":"reporting","shares":347000,"book_value_yen":121797000,"prior_shares":347000,"prior_book_value_yen":109999000,"purpose_ja":"医薬品分野における取引・協力関係の構築による企業価値向上を図るため株式を保有しております。","reciprocal":"有","pct_outstanding":0.9998292798708002,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2628015049964263,"pct_of_holder_assets":0.2253585078678978,"holder_equity_basis":"parent_only","holder_equity_yen":46345625000,"holder_total_assets_yen":54045885000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ほくやく・竹山ホールディングス","holder_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","holder_sec_code":"3055","doc_id":"S100YJPG","period_end":"2026-03-31","holder_table":"largest","shares":77400,"book_value_yen":27000000,"prior_shares":77400,"prior_book_value_yen":24000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.22301667510662804,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04175494486800798,"pct_of_holder_assets":0.01734271124385779,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ダイキン工業株式会社","holder_name_en":"DAIKIN INDUSTRIES,LTD.","holder_sec_code":"6367","doc_id":"S100YFQL","period_end":"2026-03-31","holder_table":"reporting","shares":50000,"book_value_yen":17000000,"prior_shares":50000,"prior_book_value_yen":15000000,"purpose_ja":"同社は当社の空調事業における販売先であり、相互の事業拡大や取引関係の強化を目的に株式を保有しております。","reciprocal":"無","pct_outstanding":0.1440676195779251,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0005125826991881293,"pct_of_holder_assets":0.00029263724686878144,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":3316538000000,"holder_total_assets_yen":5809240000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社タウンズ","holder_name_en":"TAUNS Laboratories,Inc.","holder_sec_code":"197A","doc_id":"S100Z3TC","period_end":"2026-06-30","holder_table":"reporting","shares":47592,"book_value_yen":12817000,"prior_shares":43344,"prior_book_value_yen":13393000,"purpose_ja":"（保有目的・業務提携等の概要）当社製品の販売先であり、取引関係の維持・強化（定量的な保有効果）定量的な保有効果の記載は困難でありますが、保有効果の経済的合理性については、長期的な取引関係の継続による売上高の推移及び配当金等を検証し、取締役会で保有の適否を判断しております。（株式が増加した理由）取引先持株会を通じた株式の取得","reciprocal":"無","pct_outstanding":0.13712932301905223,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06599715878034862,"pct_of_holder_assets":0.02872440856225382,"holder_equity_basis":"parent_only","holder_equity_yen":19420533000,"holder_total_assets_yen":44620588000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"アステナホールディングス株式会社","holder_name_en":"Astena Holdings Co., Ltd.","holder_sec_code":"8095","doc_id":"S100XN2T","period_end":"2025-11-30","holder_table":"reporting","shares":45378,"book_value_yen":12000000,"prior_shares":42933,"prior_book_value_yen":10000000,"purpose_ja":"定量的な保有効果の記載は困難ですが、主にファインケミカル事業における取引先であり、良好な関係の維持、強化を図るために保有しております。信頼関係の構築・維持強化の必要性や事業上の取引状況等に基づく保有意義、同社との取引関係等による経済合理性について経営陣が定期的に検証・審議を行い、保有の合理性があると判断しております。株式数増加の理由は、取引先持株会を通じた株式の取得であります。","reciprocal":"無","pct_outstanding":0.1307500088241417,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04380041610395299,"pct_of_holder_assets":0.01590646995665487,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":27397000000,"holder_total_assets_yen":75441000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ニプロ株式会社","holder_name_en":"NIPRO CORPORATION","holder_sec_code":"8086","doc_id":"S100YJLK","period_end":"2026-03-31","holder_table":"reporting","shares":34300,"book_value_yen":12000000,"prior_shares":34300,"prior_book_value_yen":10000000,"purpose_ja":"(保有目的) 医療用医薬品の取引先であり、取引関係を維持・強化させるため保有しています。","reciprocal":"有","pct_outstanding":0.09883038703045662,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0035845291720932454,"pct_of_holder_assets":0.0009890463120935638,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":334772000000,"holder_total_assets_yen":1213290000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ダイト株式会社","holder_name_en":"Daito Pharmaceutical Co.,Ltd.","holder_sec_code":"4577","doc_id":"S100YYNI","period_end":"2026-05-31","holder_table":"reporting","shares":16000,"book_value_yen":4000000,"prior_shares":16000,"prior_book_value_yen":4000000,"purpose_ja":"(保有目的) 当社の原薬及び製剤の販売先であり、取引関係の維持・強化を目的として保有しております。","reciprocal":"無","pct_outstanding":0.04610163826493603,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.007556008916090521,"pct_of_holder_assets":0.005457696033619407,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":52938000000,"holder_total_assets_yen":73291000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"大木ヘルスケアホールディングス株式会社","holder_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","holder_sec_code":"3417","doc_id":"S100YF0K","period_end":"2026-03-31","holder_table":"largest","shares":9539,"book_value_yen":3000000,"prior_shares":9125,"prior_book_value_yen":2000000,"purpose_ja":"・同社株式は、当社グループの事業活動の円滑化のため保有しております。・同社は、当社グループにおける主要な仕入先であり、当社の事業継続に不可欠な取引先であります。・当社グループは保有株式について、配当・取引額に加え、経営戦略上の重要性や事業上の関係等を総合的に判断し、保有の便益とリスクの見合いを勘案し保有しております。定量的な保有効果については、取引先との関係性を考慮し記載しませんが、上記方針に基づいて総合的に保有効果を判断しております。 ・2025年度は、新規商品・カテゴリーの導入等に伴う、より一層の取引関係や協力関係の強化を図るため、取引先持株会を通じて保有株式数が増加しております。","reciprocal":"有","pct_outstanding":0.02748522046307655,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.008780659134812387,"pct_of_holder_assets":0.002021658703577662,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":34166000000,"holder_total_assets_yen":148393000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ボーソー油脂株式会社","holder_name_en":"BOSO OIL&FAT CO.,LTD.","holder_sec_code":"2608","doc_id":"S100JBED","period_end":"2020-03-31","holder_table":"reporting","shares":4410,"book_value_yen":1014000,"prior_shares":3503,"prior_book_value_yen":984000,"purpose_ja":"取引関係強化のため、持株会購入により増加","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.025346527525728975,"pct_of_holder_assets":0.01042021735915725,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":4000548000,"holder_total_assets_yen":9731083000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"largest","shares":5001,"book_value_yen":1000000,"prior_shares":5001,"prior_book_value_yen":1000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.014409643310184067,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.000842410304362843,"pct_of_holder_assets":0.0003119462953257967,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"largest","shares":null,"book_value_yen":null,"prior_shares":75083,"prior_book_value_yen":23000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":2,"acquisition_cost_yen":2776000,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":2252636000,"listed_yen":2243189000,"unlisted_yen":9447000,"listed_issues":14,"unlisted_issues":1,"equity_yen":12008581000,"equity_basis":"parent_only","total_assets_yen":16499607000,"assets_basis":"parent_only","pct_of_equity":18.75855273824609,"pct_of_assets":13.652664575586558,"equity_basis_label":"Parent company only — not consolidated","assets_basis_label":"Parent company only — not consolidated","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":2243189000,"issue_count":14,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":9447000,"issue_count":1,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-03-31","policy_total_yen":2066341000,"equity_yen":11480803000,"equity_basis":"parent_only","pct_of_equity":17.998227127492736,"pct_of_assets":13.818503908968074},{"year":"2023","period_end":"2023-03-31","policy_total_yen":2483290000,"equity_yen":11906669000,"equity_basis":"parent_only","pct_of_equity":20.8562949049814,"pct_of_assets":15.80550312244754},{"year":"2024","period_end":"2024-03-31","policy_total_yen":2442113000,"equity_yen":12026073000,"equity_basis":"parent_only","pct_of_equity":20.30682002346069,"pct_of_assets":15.836226239788799},{"year":"2025","period_end":"2025-03-31","policy_total_yen":1847918000,"equity_yen":11610351000,"equity_basis":"parent_only","pct_of_equity":15.916125188635554,"pct_of_assets":12.317228841804504},{"year":"2026","period_end":"2026-03-31","policy_total_yen":2252636000,"equity_yen":12008581000,"equity_basis":"parent_only","pct_of_equity":18.75855273824609,"pct_of_assets":13.652664575586558}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2022","period_end":"2022-03-31","named_holdings":20,"book_value_yen":2056887000},{"year":"2023","period_end":"2023-03-31","named_holdings":20,"book_value_yen":2473835000},{"year":"2024","period_end":"2024-03-31","named_holdings":20,"book_value_yen":2432660000},{"year":"2025","period_end":"2025-03-31","named_holdings":16,"book_value_yen":1838467000},{"year":"2026","period_end":"2026-03-31","named_holdings":15,"book_value_yen":2243184000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}